Kori M, Kamiya K, Kurihara E, Sugihara H
Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan.
Chem Pharm Bull (Tokyo). 1991 Apr;39(4):922-6. doi: 10.1248/cpb.39.922.
The selective 5-HT2-receptor antagonist, methyl (+/-)-cis-3-hydroxy-4-[3-(4-phenyl-1-piperazinyl)propyl]-3,4-dihydro-2H- 1,5-benzoxathiepin-4-carboxylate hydrochloride ((+/-)-CV-5197) was resolved in high optical purity using (R)-(-)- and (S)-(+)-1,1'-binaphthyl-2,2'-diyl hydrogen phosphates ((R)-(-)- and (S)-(+)-BNP). The absolute configuration of (+)-CV-5197 was determined to be 3S,4R by X-ray crystallographic analysis. In the binding assay, it was demonstrated that (+)-CV-5197 was a more active isomer (IC50 = 23 nM +/- 6.3) for 5-HT2 receptor binding than the (-)-enantiomer (IC50 = 1600 nM +/- 82). (+)-CV-5197 completely inhibited the 5-HT-induced contraction of the isolated pig coronary artery at a concentration of 3 x 10(-7) M, whereas (-)-CV-5197 showed little antagonistic activity, even at 3 x 10(-4) M. Thus, the agreement between the results of the binding assays and the biological activities for the 3S,4R enantiomer of CV-5197 suggests that its physiological activity is probably exerted through 5-HT2-receptor antagonism.
选择性5-羟色胺2型受体拮抗剂,甲基(±)-顺式-3-羟基-4-[3-(4-苯基-1-哌嗪基)丙基]-3,4-二氢-2H-1,5-苯并氧硫杂环庚烷-4-羧酸盐酸盐((±)-CV-5197)使用(R)-(-)-和(S)-(+)-1,1'-联萘基-2,2'-二磷酸氢酯((R)-(-)-和(S)-(+)-BNP)被拆分为高光学纯度。通过X射线晶体学分析确定(+)-CV-5197的绝对构型为3S,4R。在结合试验中,证明(+)-CV-5197是5-HT2受体结合的活性更高的异构体(IC50 = 23 nM±6.3),比(-)-对映体(IC50 = 1600 nM±82)更具活性。(+)-CV-5197在3×10(-7)M的浓度下完全抑制5-HT诱导的离体猪冠状动脉收缩,而(-)-CV-5197即使在3×10(-4)M时也几乎没有拮抗活性。因此,CV-5197的3S,4R对映体的结合试验结果与生物活性之间的一致性表明其生理活性可能是通过5-HT2受体拮抗作用发挥的。